特应性皮炎合并克罗恩病1例
A Case of Atopic Dermatitis Combined with Crohn’s Disease
DOI: 10.12677/acm.2025.1572078, PDF,   
作者: 杨温雅：暨南大学第一临床医学院，广东 广州；韩红丽, 龚晓兵*：暨南大学附属第一医院全科医学科，广东 广州
关键词: 特应性皮炎；克罗恩病；关联性；Atopic Dermatitis； Crohn’s Disease； Relevance
摘要: 22岁男性患者，全身皮疹多年，反复腹痛3月余，加重3天入院。3个月前出现上腹部阵发性隐痛，进食后加重，便后缓解，且伴全身多处皮疹，在排除其他可能的原因后，完善胃肠镜并行病理检查，诊断为末端性回肠炎(克罗恩病？)、特应性皮炎，予JAK抑制剂乌帕替尼缓释片15 mg，po，qd治疗，后患者腹痛及全身皮疹好转出院。
Abstract: A 22-year-old male patient, generalised rash for many years, recurrent abdominal pain for over 3 months, admitted after worsening for 3 days. Three months ago, intermittent dull pain occurred under the xiphoid process, worsening after meals and alleviated after defecation, accompanied by generalised rash in multiple areas. After ruling out other possible causes, gastrointestinal endoscopy and pathological examination were performed, diagnosing terminal ileitis (Crohn’s disease?), atopic dermatitis. Treatment involved 15 mg of the JAK inhibitor upadacitinib sustained release tablets, taken orally once daily, leading to improvement in abdominal pain and generalised rash upon discharge.
文章引用：杨温雅, 韩红丽, 龚晓兵. 特应性皮炎合并克罗恩病1例[J]. 临床医学进展, 2025, 15(7): 959-964. https://doi.org/10.12677/acm.2025.1572078

参考文献

[1] 韦子钧, 赵淑, 于敏, 等. 特应性皮炎发病机制与治疗研究进展[J]. 现代中西医结合杂志, 2024, 33(22): 3201-3207.
[2] Lee, H., Lee, J.H., Koh, S. and Park, H. (2020) Bidirectional Relationship between Atopic Dermatitis and Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Journal of the American Academy of Dermatology, 83, 1385-1394. [Google Scholar] [CrossRef] [PubMed]
[3] Chiesa Fuxench, Z.C., Wan, J., Wang, S., Syed, M.N., Shin, D.B., Abuabara, K., et al. (2023) Risk of Inflammatory Bowel Disease in Patients with Atopic Dermatitis. JAMA Dermatology, 159, 1085-1092. [Google Scholar] [CrossRef] [PubMed]
[4] de Lusignan, S., Alexander, H., Broderick, C., Dennis, J., McGovern, A., Feeney, C., et al. (2022) Atopic Dermatitis and Risk of Autoimmune Conditions: Population-Based Cohort Study. Journal of Allergy and Clinical Immunology, 150, 709-713. [Google Scholar] [CrossRef] [PubMed]
[5] Bezzio, C., Della Corte, C., Vernero, M., Di Luna, I., Manes, G. and Saibeni, S. (2022) Inflammatory Bowel Disease and Immune-Mediated Inflammatory Diseases: Looking at the Less Frequent Associations. Therapeutic Advances in Gastroenterology, 15, 1-16. [Google Scholar] [CrossRef] [PubMed]
[6] Lu, Z., Zeng, N., Cheng, Y., Chen, Y., Li, Y., Lu, Q., et al. (2021) Atopic Dermatitis and Risk of Autoimmune Diseases: A Systematic Review and Meta-Analysis. Allergy, Asthma & Clinical Immunology, 17, Article No. 96. [Google Scholar] [CrossRef] [PubMed]
[7] Weng, Y., Juan, C., Ho, H.J., Chang, Y., Wu, C. and Chen, Y. (2020) Atopic Dermatitis Does Not Increase the Risk of Inflammatory Bowel Disease: A Nationwide Cohort Study. The Journal of Dermatology, 48, 168-174. [Google Scholar] [CrossRef] [PubMed]
[8] Zheng, D., Xu, Q. and Liu, Y. (2024) Atopic Disease and Inflammatory Bowel Disease: A Bidirectional Mendelian Randomization Study. Medicine, 103, e40143. [Google Scholar] [CrossRef] [PubMed]
[9] Blauvelt, A., Teixeira, H.D., Simpson, E.L., Costanzo, A., De Bruin-Weller, M., Barbarot, S., et al. (2021) Risankizumab versus Placebo for Moderate-to-Severe Atopic Dermatitis. New England Journal of Medicine, 384, 1101-1112.
[10] Neurath, M.F. (2014) Cytokines in Inflammatory Bowel Disease. Nature Reviews Immunology, 14, 329-342. [Google Scholar] [CrossRef] [PubMed]
[11] 王木岭, 万苹, 李娅琳, 等. 克罗恩病发病机制及其药物治疗的研究进展[J]. 中国医院药学杂志, 2020, 40(17): 1891-1895.
[12] Fang, Z., Li, L., Zhang, H., Zhao, J., Lu, W. and Chen, W. (2021) Gut Microbiota, Probiotics, and Their Interactions in Prevention and Treatment of Atopic Dermatitis: A Review. Frontiers in Immunology, 12, Article ID: 720393.
[13] Mahmud, M.R., Akter, S., Tamanna, S.K., Mazumder, L., Esti, I.Z., Banerjee, S., et al. (2022) Impact of Gut Microbiome on Skin Health: Gut-Skin Axis Observed through the Lenses of Therapeutics and Skin Diseases. Gut Microbes, 14, Article ID: 2096995. [Google Scholar] [CrossRef] [PubMed]
[14] De Pessemier, B., Grine, L., Debaere, M., Maes, A., Paetzold, B. and Callewaert, C. (2021) Gut-Skin Axis: Current Knowledge of the Interrelationship between Microbial Dysbiosis and Skin Conditions. Microorganisms, 9, Article No. 353. [Google Scholar] [CrossRef] [PubMed]
[15] Zysk, W., Mesjasz, A., Trzeciak, M., Horvath, A. and Plata-Nazar, K. (2024) Gastrointestinal Comorbidities Associated with Atopic Dermatitis—A Narrative Review. International Journal of Molecular Sciences, 25, Article No. 1194. [Google Scholar] [CrossRef] [PubMed]
[16] Padda, I.S., Bhatt, R., Patel, P. and Parmar, M. (2024) Upadacitinib. StatPearls Publishing.
[17] Novielli, D., Foti, C., Principi, M., Mortato, E., Romita, P., Dell’Aquila, P., et al. (2023) Upadacitinib in Concurrent Crohn’s Disease, Atopic Dermatitis and Alopecia Areata: A Case Report. Journal of the European Academy of Dermatology and Venereology, 38, e8-e10. [Google Scholar] [CrossRef] [PubMed]
[18] Panés, J., Sandborn, W.J., Schreiber, S., Sands, B.E., Vermeire, S., D’Haens, G., et al. (2017) Tofacitinib for Induction and Maintenance Therapy of Crohn’s Disease: Results of Two Phase IIb Randomised Placebo-Controlled Trials. Gut, 66, 1049-1059. [Google Scholar] [CrossRef] [PubMed]
[19] Levy, L.L., Urban, J. and King, B.A. (2015) Treatment of Recalcitrant Atopic Dermatitis with the Oral Janus Kinase Inhibitor Tofacitinib Citrate. Journal of the American Academy of Dermatology, 73, 395-399. [Google Scholar] [CrossRef] [PubMed]
[20] 中国医师协会皮肤科医师分会, 中华医学会皮肤性病学分会, 中国医疗保健国际交流促进会皮肤医学分会, 等. 特应性皮炎治疗药物应用管理专家共识(2024版) [J]. 中华皮肤科杂志, 2024, 57(2): 97-108.
[21] 中华医学会消化病学分会炎症性肠病学组, 中国炎症性肠病诊疗质量控制评估中心. 中国克罗恩病诊治指南(2023年·广州) [J]. 中华炎性肠病杂志, 2024, 8(1): 2-32.

为你推荐